

Arbuckle Stuart A  
Form 4  
February 06, 2019

**FORM 4**

**UNITED STATES SECURITIES AND EXCHANGE COMMISSION**  
**Washington, D.C. 20549**

Check this box  
if no longer  
subject to  
Section 16.  
Form 4 or  
Form 5  
obligations  
may continue.  
See Instruction  
1(b).

**STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP OF  
SECURITIES**

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934,  
Section 17(a) of the Public Utility Holding Company Act of 1935 or Section  
30(h) of the Investment Company Act of 1940

## OMB APPROVAL

OMB  
Number: 3235-0287  
Expires: January 31,  
2005  
Estimated average  
burden hours per  
response... 0.5

(Print or Type Responses)

1. Name and Address of Reporting Person \*  
Arbuckle Stuart A

2. Issuer Name **and** Ticker or Trading  
Symbol  
VERTEX PHARMACEUTICALS  
INC / MA [VRTX]

5. Relationship of Reporting Person(s) to  
Issuer

(Check all applicable)

(Last) (First) (Middle)  
C/O VERTEX  
PHARMACEUTICALS  
INCORPORATED, 50 NORTHERN  
AVENUE

3. Date of Earliest Transaction  
(Month/Day/Year)  
02/04/2019

\_\_\_\_ Director \_\_\_\_ 10% Owner  
\_X\_ Officer (give title below) \_\_\_\_ Other (specify below)  
EVP/Chief Commercial Officer

(Street)  
BOSTON, MA 02210

4. If Amendment, Date Original  
Filed(Month/Day/Year)

6. Individual or Joint/Group Filing(Check  
Applicable Line)  
\_X\_ Form filed by One Reporting Person  
\_\_\_\_ Form filed by More than One Reporting  
Person

(City) (State) (Zip)

**Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned**

1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)	4. Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D) Price			
Common Stock	02/04/2019		M		4,250	A \$ 109.41	51,002	D	
Common Stock	02/04/2019		M		2,155	A \$ 91.05	53,157	D	
Common Stock	02/04/2019		M		1,554	A \$ 86.52	54,711	D	
Common Stock	02/04/2019		S <sup>(1)</sup>		1,400	D \$ 184.81	53,311	D	

Edgar Filing: Arbuckle Stuart A - Form 4

Common Stock	02/04/2019	S <sup>(1)</sup>	12,565	D	<sup>(2)</sup> <sup>(3)</sup> \$ 186.1 <sup>(3)</sup> <sup>(4)</sup>	40,746	D
Common Stock	02/04/2019	S <sup>(1)</sup>	4,044	D	\$ 186.84 <sup>(3)</sup> <sup>(5)</sup>	36,702	D
Common Stock	02/04/2019	S <sup>(1)</sup>	300	D	\$ 188.07 <sup>(3)</sup> <sup>(6)</sup>	36,402	D
Common Stock						140	I 401(k)

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

**Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB control number.**

SEC 1474  
(9-02)

**Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned**  
(e.g., puts, calls, warrants, options, convertible securities)

1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)	5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4, and 5)	6. Date Exercisable and Expiration Date (Month/Day/Year)	7. Title and Amount of Underlying Securities (Instr. 3 and 4)	8. Derivative Securities (Instr. 3 and 4)
				Code	V	(A)	(D)	Amount or Number of Shares
Stock Option (Right to Buy)	\$ 109.14	02/04/2019		M		4,250	<sup>(7)</sup> 02/02/2025	Common Stock 4,250
Stock Option (Right to Buy)	\$ 91.05	02/04/2019		M		2,155	<sup>(8)</sup> 02/01/2026	Common Stock 2,155
Stock Option (Right to Buy)	\$ 86.52	02/04/2019		M		1,554	<sup>(9)</sup> 02/02/2027	Common Stock 1,554

## Reporting Owners

Reporting Owner Name / Address	Relationships			
	Director	10% Owner	Officer	Other
Arbuckle Stuart A C/O VERTEX PHARMACEUTICALS INCORPORATED 50 NORTHERN AVENUE BOSTON, MA 02210			EVP\Chief Commercial Officer	

## Signatures

/s/ Omar White,  
Attorney-in-Fact

02/06/2019

\_\_Signature of Reporting Person

Date

## Explanation of Responses:

- \* If the form is filed by more than one reporting person, *see* Instruction 4(b)(v).
- \*\* Intentional misstatements or omissions of facts constitute Federal Criminal Violations. *See* 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
- (1) Transaction made pursuant to Mr. Arbuckle's company approved trading plan under Rule 10b5-1.
  - (2) Open market sales reported on this line occurred at a weighted average price of \$184.81(range \$184.50 to \$185.50).
  - (3) Mr. Arbuckle undertakes to provide (upon request by the SEC staff, the issuer or a security holder of the issuer) full information regarding the number of shares sold at each separate price.
  - (4) Open market sales reported on this line occurred at a weighted average price of \$186.10 (range \$185.55 to \$186.50).
  - (5) Open market sales reported on this line occurred at a weighted average price of \$186.84 (range \$186.52 to \$187.33).
  - (6) Open market sales reported on this line occurred at a weighted average price of \$188.07(range \$187.51 to \$188.35).
  - (7) The option vests in 16 quarterly installments from 02/03/2015.
  - (8) The option vests in 16 quarterly installments from 02/02/2016.
  - (9) The option vests in 16 quarterly installments from 02/03/2017.

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, *see* Instruction 6 for procedure. Potential persons who are to respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB number.